Deshaies
Martin Deshaies, Saint-Lazare CA
Patent application number | Description | Published |
---|---|---|
20140060891 | STANDOFF DEVICE AND METHOD OF INSTALLATION OF HARNESS - A device connects a wire harness to a structure. A fixation portion of the device is secured to the structure. A spacing portion is connected to the fixation portion and to a connector portion. A retaining clip on the connector portion deforms when a wire harness connector component moves axially toward the fixation portion. The clip opposes an abutment edge against the component into engagement position when the component is past the clip to prevent it from moving back onto the clip. An abutment surface contacts another portion of the component in engagement position to prevent further axial movement of the component toward the fixation portion. The component is held captive between the edge and the abutment surface. Also provided are a cable support for connecting the wire harness to the device, a method for connecting and disconnecting the wire harness to a structure with the device, and an aircraft. | 03-06-2014 |
Raymond Deshaies, Montreal CA
Patent application number | Description | Published |
---|---|---|
20100193270 | HYBRID ELECTRIC PROPULSION SYSTEM - A hybrid electric propulsion system for a vehicle. The system includes an internal combustion engine ( | 08-05-2010 |
Raymond Deshaies, Claremont, CA US
Patent application number | Description | Published |
---|---|---|
20090192084 | Compositions and method of treating hypoxia-associated diseases - Hypoxia, a state of lower than normal tissue oxygen tension, has recently been implicated in a host of human diseases, including cancer, heart disease, and neurological disorders. Novel associations between p97 and other proteins, including UBX-domain-containing proteins (UBX-polypeptides), HIF1α, and a variety of E3 ligases are provided herein. The disclosure provides complexes comprising UBX-domain-containing polypeptides (UBX-polypeptides) and other polypeptides involved in the degradation of ubiquitinated proteins. In addition, the disclosure provides uses for active agents that modulate protein-protein complex formation between an UBX-polypeptide and its complementary-binding substrate. For example, the disclosure provides methods for treating or preventing hypoxia-related disorders or conditions in a patient or a cell by administration of an active agent that modulates the activity of an UBX-polypeptide and/or its complementary binding-substrate. Furthermore, the disclosure provides uses for active agents that modulate HIF1α activity; such agents may be used to modulate processes that are regulated by HIF1α. The disclosure also provides many screening assays to identify test agents that modulate complex formation between an UBX-polypeptide and its complementary-binding substrate or methods for evaluating modes of action and/or effects of active agents that have already been identified as modulators of an UBX-polypeptide and/or its complementary-binding substrate. | 07-30-2009 |
20090253717 | Inhibitors of p97 - One aspect of the invention relates to compounds that inhibit the activity of p97, such as by binding covalently to a cysteine residue in the active site. In certain embodiments, the invention relates to the treatment of disease, such as cancer, comprising administering a compound of the invention. | 10-08-2009 |
Raymond J. Deshaies, Claremont, CA US
Patent application number | Description | Published |
---|---|---|
20110288082 | METHODS AND COMPOSITIONS FOR INHIBITION OF THE TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE - Compounds of Formulas I-XLIII are identified as direct inhibitors of p97 ATPase or of the degradation of a p97-dependent ubiquitin-proteasome system (UPS) substrate. Methods and compositions are disclosed for inhibiting p97 ATPase and the degradation of a p97-dependent UPS substrate, and for identifying inhibitors thereof | 11-24-2011 |
Raymond J. Deshaies, Pasadena, CA US
Patent application number | Description | Published |
---|---|---|
20140235548 | COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION - Compounds, pharmaceutical compositions, and methods of using such compounds to treat or prevent diseases or disorders associated with or mediated by JAMM proteins are disclosed. The compounds and compositions inhibit the enzymatic activity of a JAMM domain, including the JAMM domain of the CSN5 subunit of the COP9-signalsome (CSN), the JAMM domain of the Rpn11/Poh1/Psmd14 subunit of the 26S proteasome, the JAMM domain of AMSH, the JAMM domain of AMSH-LP, the JAMM domain of BRCC36, among other JAMM domains. | 08-21-2014 |
20140271926 | METHODS OF USE OF GLUTAMINE SYNTHETASE INHIBITORS - A method of treating neoplastic growth in a subject includes administering a glutamine synthetase (GS) inhibitor to the subject having neoplastic growth. A glutamine synthetase inhibitor may be administered in combination with thalidomide, lenalidomide and/or pomalidomide. Responsiveness to thalidomide, lenalidomide or pomalidomide therapy is determined by the expression levels of glutamine synthetase in neoplastic cells. | 09-18-2014 |